Department of Urology, Postgraduate Institute of Medical Education and Research, Advance Urology Centre, B Block, Level II, Nehru Hospital Building, Chandigarh, 160012, India.
World J Urol. 2020 Apr;38(4):929-938. doi: 10.1007/s00345-019-02862-z. Epub 2019 Jun 28.
Stent-related symptoms are frequent following stent placement for various indications. Use of PDE inhibitors has expanded beyond their classical indication and has been tried in patients with stent-related symptoms. The systematic review was conducted to ascertain the efficacy of PDE inhibitors in ameliorating stent-related symptoms.
We performed systematic review and metanalysis on the use of PDE inhibitors for stent-related symptoms in patients who underwent stent placement for various reasons (postpercutaneous nephrolithotomy or ureterorenoscopy). We followed PRISMA guidelines while conducting this review and study protocol was registered with PROSPERO (CRD42019121781) RESULTS: Three studies with 280 participants were included in this review. There was considerable heterogeneity across all the outcome parameters assessed; thus, random-effect model was used for analysis. Comparison of PDE inhibitors with control arm revealed that PDE inhibitors were significantly more effective than placebo in all but one domain (Work performance) of the USSQ. On comparison with alfa blockers, PDE inhibitors were found to be equally effective for urinary symptoms, general health, and body pain parameters, but sexual health parameters improved significantly with PDE inhibitors.
PDE inhibitors can be considered an option for patients with stent-related symptoms especially in patients with sexual dysfunction. Due to various limitations of the studies included in this review, we recommend conducting further high-quality studies.
支架相关症状在各种适应证下放置支架后很常见。磷酸二酯酶抑制剂(PDE)的使用已经超出了其经典适应证,并已在支架相关症状患者中进行了尝试。本系统评价旨在确定 PDE 抑制剂在改善支架相关症状方面的疗效。
我们对接受各种原因(经皮肾镜碎石取石术或输尿管镜检查)支架置入的患者使用 PDE 抑制剂治疗支架相关症状进行了系统评价和荟萃分析。我们在进行这项综述时遵循了 PRISMA 指南,并将研究方案在 PROSPERO(CRD42019121781)上进行了注册。
本综述纳入了 3 项共 280 名参与者的研究。所有评估的结局参数均存在较大异质性;因此,采用随机效应模型进行分析。与对照组相比,PDE 抑制剂在 USSQ 的所有除工作表现外的领域均显著优于安慰剂。与阿尔法受体阻滞剂相比,PDE 抑制剂在治疗尿症状、一般健康和躯体疼痛参数方面同样有效,但 PDE 抑制剂可显著改善性功能健康参数。
PDE 抑制剂可被视为支架相关症状患者的一种选择,尤其是在存在性功能障碍的患者中。由于本综述纳入的研究存在各种局限性,我们建议进行进一步的高质量研究。